173 related articles for article (PubMed ID: 19962701)
1. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study.
Andreou I; Tousoulis D; Miliou A; Tentolouris C; Zisimos K; Gounari P; Siasos G; Papageorgiou N; Papadimitriou CA; Dimopoulos MA; Stefanadis C
Atherosclerosis; 2010 May; 210(1):194-8. PubMed ID: 19962701
[TBL] [Abstract][Full Text] [Related]
2. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress.
Tousoulis D; Andreou I; Tsiatas M; Miliou A; Tentolouris C; Siasos G; Papageorgiou N; Papadimitriou CA; Dimopoulos MA; Stefanadis C
Atherosclerosis; 2011 Jan; 214(1):151-7. PubMed ID: 21122851
[TBL] [Abstract][Full Text] [Related]
3. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
Carter NJ
Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
[TBL] [Abstract][Full Text] [Related]
5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
6. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
[TBL] [Abstract][Full Text] [Related]
7. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
8. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein lowering with rosuvastatin in the METEOR study.
Peters SA; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Raichlen JS; Bots ML
J Intern Med; 2010 Aug; 268(2):155-61. PubMed ID: 20412373
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effects of long-term monotherapy with rosuvastatin in dogs with moderate heart failure.
Chello M; Spadaccio C
Cardiology; 2013; 124(1):36-7. PubMed ID: 23295545
[No Abstract] [Full Text] [Related]
11. [To treat or not to treat with statins patients with chronic heart failure?].
Hradec J
Vnitr Lek; 2009 Sep; 55(9):802-7. PubMed ID: 19785380
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
Cleland JG; McMurray JJ; Kjekshus J; Cornel JH; Dunselman P; Fonseca C; Hjalmarson A; Korewicki J; Lindberg M; Ranjith N; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
J Am Coll Cardiol; 2009 Nov; 54(20):1850-9. PubMed ID: 19892235
[TBL] [Abstract][Full Text] [Related]
13. Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study).
van der Harst P; Slart RH; Tio RA; Dunselman PH; Willemsen AT; van den Heuvel AF; Voors AA; van Veldhuisen DJ;
Am J Cardiol; 2010 Feb; 105(4):517-21. PubMed ID: 20152247
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
Nicholls SJ; Uno K; Kataoka Y
Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1383-90. PubMed ID: 22059787
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin in older patients with systolic heart failure.
Kjekshus J; Apetrei E; Barrios V; Böhm M; Cleland JG; Cornel JH; Dunselman P; Fonseca C; Goudev A; Grande P; Gullestad L; Hjalmarson A; Hradec J; Jánosi A; Kamenský G; Komajda M; Korewicki J; Kuusi T; Mach F; Mareev V; McMurray JJ; Ranjith N; Schaufelberger M; Vanhaecke J; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
N Engl J Med; 2007 Nov; 357(22):2248-61. PubMed ID: 17984166
[TBL] [Abstract][Full Text] [Related]
18. [No reason to start treatment with statins in patients with moderate to severe heart failure].
Stalenhoef AF
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):486-8. PubMed ID: 18389878
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
20. Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction.
Xu Y; Tang T; Ding Y; Yao R; Xie J; Liao M; Xiao H; Chen Y; Yu X; Fu M; Liao Y; Zhao G; Cheng X
Am J Med Sci; 2010 Aug; 340(2):121-7. PubMed ID: 20588182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]